Fluvastatin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fluvastatin: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Fluvastatin is an HMG-CoA reductase inhibitor (statin) established for treating hypercholesterolemia and hyperlipidemia. The TxGNN model’s top prediction, Hyperlipoproteinemia, is supported by 5 clinical trials and 20 publications — but the pack’s own mechanistic analysis flags this as an extension of fluvastatin’s existing core indication rather than a true novel repurposing case. Critically, official Taiwan/US label data (warnings, contraindications) is a blocking data gap, so no safety pre-assessment can yet be completed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no TFDA/US license records; original_indications empty). Fluvastatin is broadly established in the literature as a statin for hypercholesterolemia/hyperlipidemia. |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data (original_moa) is not available in this pack. Based on the repurposing rationale attached to the top prediction, fluvastatin is an HMG-CoA reductase inhibitor — it inhibits cholesterol synthesis and upregulates LDL receptor expression. This is stated explicitly to be the statin class’s own core mechanism.
Importantly, the pack itself notes this prediction is not a typical “old drug, new use” case — hyperlipoproteinemia is essentially an extension/synonym of fluvastatin’s already-established, direct indication rather than a novel therapeutic area. The mechanistic link is direct and well-characterized precisely because it reflects known statin pharmacology, not a speculative cross-disease connection.
By contrast, lower-ranked candidates in this pack (e.g., homozygous familial hypercholesterolemia, HIV infectious disease) represent more genuine repurposing hypotheses with weaker or more indirect mechanistic support — see the full candidate list below for comparison.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00726362 | N/A | Completed | 3270 | Large surveillance study comparing commercially available statins (incl. fluvastatin) in routine clinical practice for hyperlipidemia; statin-class effect validation |
| NCT01634906 | N/A | Completed | 55 | Non-randomized study of erythrocyte-bound ApoB changes after statin withdrawal; statin-class relevant, not fluvastatin-specific RCT |
| NCT00532311 | Phase 3 | Terminated | 411 | Lapaquistat acetate (not fluvastatin) added to statin background therapy in hypercholesterolemia; same lipid-lowering mechanism class only |
| NCT04608474 | Phase 4 | Completed | 81 | PCSK9 inhibitor (evolocumab) pilot in renal transplant recipients with hyperlipidemia; not fluvastatin |
| NCT03510715 | Phase 3 | Completed | 18 | Alirocumab in pediatric/adolescent homozygous FH; not fluvastatin |
Note: None of the trials above tested fluvastatin directly against hyperlipoproteinemia as a primary endpoint — evidence is class-level (statin/PCSK9i), not drug-specific for this exact indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10067240 | 1998 | RCT | Terapevticheskii arkhiv | Compared hypolipidemic effect variability of simvastatin vs. fluvastatin in primary hyperlipoproteinemia |
| 10856536 | 2000 | RCT | Atherosclerosis | FACT study: fluvastatin + bezafibrate combination efficacy/safety in mixed hyperlipidaemia (n=333) |
| 11219479 | 2001 | RCT | Clinical Therapeutics | Compared fluvastatin extended-release vs. immediate-release formulations in primary hypercholesterolemia |
| 15598476 | 2004 | RCT | Clinical Therapeutics | 12-month RCT: fluvastatin+fenofibrate vs. fluvastatin monotherapy in combined hyperlipidemia with T2DM and CHD |
| 17062478 | 2006 | RCT | Acta Paediatrica | Efficacy/safety of fluvastatin in children/adolescents with heterozygous familial hypercholesterolaemia |
| 8157036 | 1993 | RCT | European Journal of Clinical Pharmacology | Double-blind study of high-dose fluvastatin in familial hypercholesterolaemia (n=52) |
| 7604789 | 1995 | Cohort | American Journal of Cardiology | Fluvastatin effects on lipid profile and apolipoproteins in Chinese hypercholesterolemia patients (n=31) |
| 9271817 | 1997 | Cohort | Thrombosis Research | Fluvastatin and tissue factor pathway inhibitor in type IIA/IIB hyperlipidemia and acute MI |
| 11347136 | 2001 | Review | Nihon Rinsho | General review of fluvastatin pharmacology and clinical use |
| 15531000 | 2004 | Review | Clinical Therapeutics | Review of rosuvastatin (comparator statin) in hyperlipidemia management |
US Market Information
No license/authorization records are available — taiwan_regulatory.total_licenses = 0 and licenses is empty, consistent with the recorded market status of Not Marketed.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and DDI data are all recorded as data gaps in this pack — notably DG001, a Blocking-severity gap on TFDA label warnings/contraindications, which prevents any safety pre-assessment.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Evidence volume is strong (L1, 5 trials + 20 publications), but this strength comes from fluvastatin’s already-established statin pharmacology rather than a genuinely novel indication — the mechanistic rationale itself states this is a direct extension, not typical repurposing. Separately, the drug is not currently marketed in the reference jurisdiction and has no license records, and safety data (warnings/contraindications) is a Blocking gap (DG001) that must be resolved before any S1 safety review can proceed.
To proceed, the following is needed:
- TFDA/US package insert warnings and contraindications (DG001 — Blocking)
- Confirmed mechanism of action documentation (DG002 — High)
- Official original-indication license text (currently absent from the pack)
- Fluvastatin-specific (not statin-class-general or comparator-drug) trial data directly targeting hyperlipoproteinemia, to confirm this is worth tracking as a distinct repurposing candidate rather than routine label extension
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.